{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:16:29Z","timestamp":1759331789441,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.lungcan.2023.03.007","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T06:07:29Z","timestamp":1678860449000},"page":"107171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing \u226550% PD-L1: A United Kingdom health care perspective"],"prefix":"10.1016","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4859-5301","authenticated-orcid":false,"given":"Chui-ying","family":"Yip","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair","family":"Greystoke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seye","family":"Abogunrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Belleli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Rouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Jovanoski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"unstructured":"Cancer Research UK. Lung cancer statistics 2022. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/lung-cancer#heading-Zero (accessed 14 April 2022).","key":"10.1016\/j.lungcan.2023.03.007_b0005"},{"issue":"3","key":"10.1016\/j.lungcan.2023.03.007_b0010","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"unstructured":"National Lung Cancer Audit. NLCA annual report 2018 - information sheet 2018. https:\/\/www.rcplondon.ac.uk\/projects\/outputs\/nlca-annual-report-2018 (accessed 14 April 2022).","key":"10.1016\/j.lungcan.2023.03.007_b0015"},{"issue":"1","key":"10.1016\/j.lungcan.2023.03.007_b0020","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for Lung Cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.03.007_b0025","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2147\/CMAR.S187317","article-title":"Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades","volume":"11","author":"Lu","year":"2019","journal-title":"Cancer Manag. Res."},{"unstructured":"National Institute for Health and Care Excellence. Lung cancer: diagnosis and management (NICE guideline NG122). https:\/\/www.nice.org.uk\/guidance\/ng122, 2019 (accessed 14 April 2022).","key":"10.1016\/j.lungcan.2023.03.007_b0030"},{"key":"10.1016\/j.lungcan.2023.03.007_b0035","first-page":"100076","article-title":"Long-term recurrence of completely resected NSCLC","volume":"1","author":"Masago","year":"2020","journal-title":"JTO Clin. Res. Rep."},{"issue":"8","key":"10.1016\/j.lungcan.2023.03.007_b0040","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.3390\/jcm9082473","article-title":"Clinicopathological factors related to recurrence patterns of resected non-small cell lung cancer","volume":"9","author":"Shimizu","year":"2020","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.lungcan.2023.03.007_b0045","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.athoracsur.2012.03.031","article-title":"Tumor recurrence after complete resection for non-small cell lung cancer","volume":"93","author":"Taylor","year":"2012","journal-title":"Ann. Thorac. Surg."},{"unstructured":"National Institute for Health and Care Excellence. Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [TA578]. https:\/\/www.nice.org.uk\/guidance\/ta578, 2019 (accessed 14 April 2022).","key":"10.1016\/j.lungcan.2023.03.007_b0050"},{"unstructured":"National Institute for Health and Care Excellence. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer [TA654]. https:\/\/www.nice.org.uk\/guidance\/ta654, 2020 (accessed 14 April 2022).","key":"10.1016\/j.lungcan.2023.03.007_b0055"},{"key":"10.1016\/j.lungcan.2023.03.007_b0060","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.lungcan.2018.07.042","article-title":"Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study","volume":"124","author":"Chouaid","year":"2018","journal-title":"Lung Cancer"},{"unstructured":"European Medicines Agency. Tecentriq 1,200 mg concentrate for solution for infusion. https:\/\/www.medicines.org.uk\/emc\/product\/8442\/smpc, 2021 (accessed 14 April 2022).","key":"10.1016\/j.lungcan.2023.03.007_b0065"},{"unstructured":"National Institute for Health and Care Excellence. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [TA823]. https:\/\/www.nice.org.uk\/guidance\/ta823, 2022 (accessed 28 September 2022).","key":"10.1016\/j.lungcan.2023.03.007_b0070"},{"unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. http:\/\/www.nice.org.uk\/article\/PMG9\/chapter\/Foreword, 2013 (accessed 17 April 2018).","key":"10.1016\/j.lungcan.2023.03.007_b0075"},{"issue":"10308","key":"10.1016\/j.lungcan.2023.03.007_b0080","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"doi-asserted-by":"crossref","unstructured":"Felip E, Altorki NK, Zhou C. Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: sub-analysis from the pivotal phase III IMpower010 study. Presented at: European Society for Medical Oncology 2022, 9-13 September 2022, Paris, France.","key":"10.1016\/j.lungcan.2023.03.007_b0085","DOI":"10.1016\/j.annonc.2022.02.090"},{"issue":"7","key":"10.1016\/j.lungcan.2023.03.007_b0090","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","article-title":"et al., Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients\u2019 data","volume":"14","author":"Mauguen","year":"2013","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.lungcan.2023.03.007_b0095","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1111\/1759-7714.13669","article-title":"Characteristics of surgically resected non-small cell lung cancer patients with post-recurrence cure","volume":"11","author":"Sonoda","year":"2020","journal-title":"Thorac Cancer"},{"unstructured":"National Institute for Health and Care Excellence. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3852]. Committee papers. https:\/\/www.nice.org.uk\/guidance\/ta823\/documents\/committee-papers, 2022 (accessed 29 October 2022).","key":"10.1016\/j.lungcan.2023.03.007_b0100"},{"issue":"1","key":"10.1016\/j.lungcan.2023.03.007_b0105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1378\/chest.09-2361","article-title":"Late recurrence of non-small cell lung cancer more than 5 years after complete resection: incidence and clinical implications in patient follow-up","volume":"138","author":"Maeda","year":"2010","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.lungcan.2023.03.007_b0110","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/JTO.0b013e318241f80b","article-title":"Long-term excess mortality for survivors of non-small cell lung cancer in the Netherlands","volume":"7","author":"Janssen-Heijnen","year":"2012","journal-title":"J. Thorac. Oncol."},{"unstructured":"National Institute for Health and Care Excellence. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [TA531]. https:\/\/www.nice.org.uk\/guidance\/ta531 , 2018 (accessed 15 March 2021).","key":"10.1016\/j.lungcan.2023.03.007_b0115"},{"unstructured":"National Institute for Health and Care Excellence. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer [TA557]. https:\/\/www.nice.org.uk\/guidance\/ta557 , 2019 (accessed 1 September 2020).","key":"10.1016\/j.lungcan.2023.03.007_b0120"},{"issue":"6","key":"10.1016\/j.lungcan.2023.03.007_b0125","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.clon.2012.03.005","article-title":"The management of lung cancer: a UK survey of oncologists","volume":"24","author":"Prewett","year":"2012","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"issue":"6","key":"10.1016\/j.lungcan.2023.03.007_b0130","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/j.cllc.2017.05.005","article-title":"Comparison of radiotherapy and chemoradiotherapy for locoregional recurrence of non-small-cell lung cancer developing after surgery","volume":"18","author":"Nakamichi","year":"2017","journal-title":"Clin. Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2023.03.007_b0135","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.1390","article-title":"Association of long-term outcomes and survival with multidisciplinary salvage treatment for local and regional recurrence after stereotactic ablative radiotherapy for early-stage lung cancer","volume":"1","author":"Brooks","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.lungcan.2023.03.007_b0140","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2016.11.002","article-title":"Impact of age and comorbidity on treatment of non-small cell lung cancer recurrence following complete resection: a nationally representative cohort study","volume":"102","author":"Wong","year":"2016","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2023.03.007_b0145","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/COC.0b013e31826b9950","article-title":"Reirradiation for locoregionally recurrent lung cancer: outcomes in small cell and non-small cell lung carcinoma","volume":"37","author":"Kruser","year":"2014","journal-title":"Am. J. Clin. Oncol."},{"unstructured":"National Institute for Health and Care Excellence. NICE pathways: treating non-small cell lung cancer, 2021. https:\/\/pathways.nice.org.uk\/pathways\/lung-cancer#path=view%3A\/pathways\/lung-cancer\/treating-non-small-cell-lung-cancer.xml&content=view-index, 2021 (accessed 29 October 2022).","key":"10.1016\/j.lungcan.2023.03.007_b0150"},{"unstructured":"National Institute for Health and Care Excellence. Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy [TA520]. https:\/\/www.nice.org.uk\/guidance\/ta520, 2018 (accessed 15 March 2021).","key":"10.1016\/j.lungcan.2023.03.007_b0155"},{"unstructured":"National Institute for Health and Care Excellence. Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer [TA584]. https:\/\/www.nice.org.uk\/guidance\/ta584, 2019 (accessed 15 March 2021).","key":"10.1016\/j.lungcan.2023.03.007_b0160"},{"issue":"5","key":"10.1016\/j.lungcan.2023.03.007_b0165","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","article-title":"Populating an economic model with health state utility values: moving toward better practice","volume":"13","author":"Ara","year":"2010","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.lungcan.2023.03.007_b0170","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jval.2010.10.029","article-title":"Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available","volume":"14","author":"Ara","year":"2011","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.lungcan.2023.03.007_b0175","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/JTO.0b013e3181f77a6a","article-title":"Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer","volume":"5","author":"Jang","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2023.03.007_b0180","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/JTO.0b013e318299243b","article-title":"Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting","volume":"8","author":"Chouaid","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"24","key":"10.1016\/j.lungcan.2023.03.007_b0185","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jnci\/djj496","article-title":"Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non\u2013small-cell lung cancer","volume":"98","author":"van den Hout","year":"2006","journal-title":"J. Natl Cancer Inst."},{"unstructured":"National Health Service. Drugs and pharmaceutical electronic market information tool (eMIT). https:\/\/www.gov.uk\/government\/publications\/drugs-and-pharmaceutical-electronic-market-information-emit, 2021 (accessed 1 February 2021).","key":"10.1016\/j.lungcan.2023.03.007_b0190"},{"unstructured":"National Institute for Health and Care Excellence. British National Formulary. https:\/\/www.nice.org.uk\/bnf-uk-only, 2021 (accessed 29 October 2022).","key":"10.1016\/j.lungcan.2023.03.007_b0195"},{"unstructured":"National Health Service. National Cost Collection for the NHS 2019\/20. https:\/\/www.england.nhs.uk\/national-cost-collection\/, 2021 (accessed 29 October 2022).","key":"10.1016\/j.lungcan.2023.03.007_b0200"},{"unstructured":"National Institute for Health and Care Excellence. Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non\u2011small\u2011cell lung cancer [TA347]. https:\/\/www.nice.org.uk\/guidance\/ta347, 2015 (accessed 29 October 2022).","key":"10.1016\/j.lungcan.2023.03.007_b0205"},{"unstructured":"Personal Social Services Research Unit. Unit costs of health and social care 2020. https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/unit-costs-2020\/, 2020 (accessed 18 April 2022).","key":"10.1016\/j.lungcan.2023.03.007_b0210"},{"unstructured":"National Institute for Health and Care Excellence. Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer [TA705]. https:\/\/www.nice.org.uk\/guidance\/ta705, 2021 (accessed 29 October 2022).","key":"10.1016\/j.lungcan.2023.03.007_b0215"},{"unstructured":"Scottish Medicines Consortium. Atezolizumab (Tecentriq\u00ae) is accepted for restricted use within NHS Scotland. https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/atezolizumab-tecentriq-for-nsclc-fullsubmission-133618, 2018 (accessed 29 October 2022).","key":"10.1016\/j.lungcan.2023.03.007_b0220"},{"doi-asserted-by":"crossref","unstructured":"Das M, Ogale S, Johnson A, et al. Cost-effectiveness of atezolizumab for adjuvant treatment of patients with stage II-IIIA PD-L1+ non-small cell lung cancer. Presented at: IASLC 2022 World Conference on Lung Cancer, Vienna, Austria, 6\u20139 August 2022. Abstract EP04.01-017.","key":"10.1016\/j.lungcan.2023.03.007_b0225","DOI":"10.1016\/j.jtho.2022.07.429"},{"doi-asserted-by":"crossref","unstructured":"Plessala I, Chouaid C, Souquet PJ, et al. Cost-effectiveness analysis of atezolizumab as adjuvant treatment of patients with stage II-IIIA non-small cell lung cancer, with PD-L1 \u226550% of tumor cells, in France. Presented at: ISPOR 2022 Annual Meeting, Washington, DC, 15\u201318 May 2022. Abstract EE324.","key":"10.1016\/j.lungcan.2023.03.007_b0230","DOI":"10.1016\/j.jval.2022.09.570"},{"doi-asserted-by":"crossref","unstructured":"M\u00e4nnik T, Jovanoski N, Vuojolainen M, et al. Cost-effectiveness analysis of atezolizumab as adjuvant treatment in adult patients following complete resection and platinum-based chemotherapy with non-small cell lung cancer (NSCLC) in Finland. Presented at: ISPOR 2022 Annual Meeting, Washington, DC, 15\u201318 May 2022. Abstract EE209.","key":"10.1016\/j.lungcan.2023.03.007_b0235","DOI":"10.1016\/j.jval.2022.09.458"},{"doi-asserted-by":"crossref","unstructured":"Escudero V, Collado R, de Castro J, et al. Cost-effectiveness analysis of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and PD-L1\u226550% expression. Presented at: ISPOR 2022 Annual Meeting, Washington, DC, 15\u201318 May 2022. Abstract EE495.","key":"10.1016\/j.lungcan.2023.03.007_b0240","DOI":"10.1016\/j.jval.2022.09.738"},{"key":"10.1016\/j.lungcan.2023.03.007_b0245","article-title":"Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy","volume":"12","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"unstructured":"National Institute for Health and Care Excellence. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [ID3835]. Committee papers 2021. https:\/\/www.nice.org.uk\/guidance\/ta761, 2021 (accessed 29 October 2022).","key":"10.1016\/j.lungcan.2023.03.007_b0250"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223000946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223000946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:03:03Z","timestamp":1759237383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223000946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":50,"alternative-id":["S0169500223000946"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.03.007","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing \u226550% PD-L1: A United Kingdom health care perspective","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107171"}}